Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

196 Applying Pharmacogenomics in Therapeutics
5. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, Lange C,
et al. (2011). Genomewide association between GLCCI1 and response to glucocorticoid
therapy in asthma. New England Journal of Medicine, 365: 1173–1183.
6. Yip V, Pirmohamed M. (2013). Expanding role of pharmacogenomics in the management
of cardiovascular disorders. American Journal of Cardiovascular Drugs, 13: 151–162.
7. Jiayi L, Wang S, Barone J, Malone B. (2009). Warfarin pharmacogenomics. Pharmacy
and Therapeutics, 34: 422–427.
8. Dean L. (2013). Warfarin therapy and the genotypes CYP2C9 and VKORC1. Medical
Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology
Information (US); 2012. Bookshelf ID: NBK84174.
9. Henry I. Bussey, Ann K Wittkowsky, Elaine M. Hylek, Marie B. Walker. (2007).
Genetic testing to aid in warfarin (Coumadin) dosing? – Not Yet Ready for Prime Time.
ClotCare Online Resource.
10. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG. (2015). Limited clinical utility
of genotype-guided warfarin initiation dosing algorithms versus standard therapy:
A meta-analysis and trial sequential analysis of 11 randomized controlled trials. The
Pharmacogenomics Journal, 1–9. Apr 14. doi: 10.1038/tpj.2015.16. [Epub ahead of print].
11. Caraco Y, Blotnick S, Muszkat M. (2008). CYP2C9 genotype-guided warfarin prescribing
enhances the efficacy and safety of anticoagulation: A prospective randomized
controlled study. Clinical Pharmacology & Therapeutics, 83: 460–470.
12. Epstein RS, Moyer TP, Aubert RE, O’Kane DJ, Xia F, Verbrugge RR, Gage BF,
Teagarden JR. (2010). Warfarin genotyping reduces hospitalization rates results from
the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American
College of Cardiology, 55: 2804–2812.
13. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. (2011). In vitro
and in vivo P-glycoprotein transport characteristics of rivaroxaban. Journal of
Pharmacology and Experimental Therapeutics, 338: 372–380.
14. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. (2008). The metabolism
and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug
Metabolism and Disposition, 36: 386–399.
15. Stangier J, Clemens A. (2009). Pharmacology, pharmacokinetics, and pharmacodynamics
of dabigatran etexilate, an oral direct thrombin inhibitor. Clinical and
Applied Thrombosis/Hemostasis, 15(Suppl 1): 9S–16S.
16. Warkentin TE, Greinacher A. (2004). Heparin-induced thrombocytopenia: Recognition,
treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and
Thrombolytic Therapy. Chest, 1263(Suppl): 311S–337S.
17. Harris K, Nguyen P, Van Cott EM. (2008). Platelet PlA2 polymorphism and the risk
for thrombosis in heparin-induced thrombocytopenia. American Journal of Clinical
Pathology, 129: 282–286.
18. Carlsson LE, Lubenow N, Blumentritt C, Kempf R, Papenberg S, Schröder W, Eichler P,
Herrmann FH, Santoso S, Greinacher A. (2003). Platelet receptor and clotting factor
polymorphisms as genetic risk factors for thromboembolic complications in heparininduced
thrombocytopenia. Pharmacogenetics, 13: 253–258.
19. Ahmed I, Majeed A, Powell R. (2007). Heparin induced thrombocytopenia: Diagnosis
and management update. Postgraduate Medical Journal, 83: 575–582.
20. Burgess J, Lindeman R, Chesterman C, Chong B. (1995). Single amino acid mutation
of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.
British Journal of Haematology, 91: 761–766.
21. Arepally G, McKenzie S, Jiang X, Poncz M, Cines D. (1997). Fc gamma RIIA H/R
131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and
clinical course in patients with heparin-induced thrombocytopenia and thrombosis.
Blood, 89: 370–375.